LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model

BACKGROUND: LCZ696 (valsartan/sacubitril) therapy significantly reduced mortality in patients with heart failure (HF). Although a clinical trial (PARADISE-MI Trial) has been ongoing to examine the effects of LCZ696 in myocardial infarction (MI) patients, the effects of LCZ696 on remodeling of cardia...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Po-Cheng, Lin, Shien-Fong, Chu, Yen, Wo, Hung-Ta, Lee, Hui-Ling, Huang, Yu-Chang, Wen, Ming-Shien, Chou, Chung-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739798/
https://www.ncbi.nlm.nih.gov/pubmed/31772612
http://dx.doi.org/10.1155/2019/6032631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739798/
https://www.ncbi.nlm.nih.gov/pubmed/31772612
http://dx.doi.org/10.1155/2019/6032631

Ejemplares similares